Can the FDA Make Up Its Mind Already?

It isn't very often that an agency sometimes accused of over-regulating an industry can be ridiculed for not regulating enough, but that's exactly where the Food and Drug Administration finds itself. And this time the criticism is coming from pharmaceutical companies themselves. Companies developing generic biologic drugs, which are often costlier and more complicated to manufacture than small molecules, have only loose guidelines on what the agency wants to see for approval. Additionally, the Biosimilar User Fee Act of 2012 -- meant to clarify development procedures -- only made things worse.

The problem gets even worse when you consider that the European Medicine Agency has a clear-cut roadmap for biosimilar drugs. In fact, more than a dozen of the generics have been approved on the continent. Why should cheaper treatments be available in one market and not another due to a simple lack of communication?

The market opportunity in the United States could be huge. Take a look at some of the top biosimilar companies waiting for the FDA to make up its mind.  

  1. Amgen (NASDAQ: AMGN  ) is looking to launch six biosimilars beginning in 2017 for drugs such as Herceptin, Humira, Remicade, and Rituxan. The company believes biosimilars represent a multibillion-dollar opportunity.  
  2. Momenta (NASDAQ: MNTA  ) and Baxter (NYSE: BAX  ) are collaborating on up to six biosimilars for autoimmune diseases and oncology. Three have already been identified, and one should have an investigational new drug application submitted next year.
  3. Novartis (NYSE: NVS  ) wants its generic business, Sandoz, to cement its role as a world-leading biosimilar company. Already controlling half of the global biosimilar market, Sandoz is currently developing 10 molecules to add to its portfolio.  
  4. Hospira (UNKNOWN: HSP.DL  ) offers services ranging from contract manufacturing to software, but it, too, wants to add a biosimilar program. The company is developing generic versions of Epogen, Herceptin, Neulasta, Neupogen, and Remicade.

There is a lot at stake, and plenty of companies that are nudging the FDA clear things up. In the following video, Fool contributor Maxx Chatsko breaks down the industry's frustration and what can be done to resolve the issue.

Can biosimilars give your portfolio a boost? The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On August 05, 2013, at 5:25 PM, EichAmgen wrote:

    As a global company developing biosimilars, Amgen views the regulatory landscape differently than the author and believes that misinformation underpins an unwarranted critique of the U.S. FDA.

    The medicines discussed here are advanced therapies made from living cells, used to address serious illnesses. Biosimilars are versions of these biologic medicines that are both expected and allowed to be similar to, not the same as, the original biologic medicine. Biosimilars are developed to exacting standards, for increasingly complex medicines and are evaluated in both structure and clinical performance. They are not generic drugs.

    From our experience and perspective, FDA has provided detailed expectations in its draft scientific guidance, seeks to provide consistent advice to sponsors across therapeutic areas and worked with industry to establish a user fee system that fosters early and frequent communication to speed development.

    Biosimilars will be available in the U.S. when patents expire. FDA and sponsors are working toward that reality so that competition can help control health care costs.

    Geoffrey Eich, Executive Director R&D Policy, Amgen Inc.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2572507, ~/Articles/ArticleHandler.aspx, 9/26/2016 4:51:32 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:00 PM
AMGN $173.53 Down -1.27 -0.73%
Amgen CAPS Rating: ****
BAX $47.20 Down -0.29 -0.61%
Baxter CAPS Rating: ****
HSP.DL $0.00 Down +0.00 +0.00%
Hospira CAPS Rating: ***
MNTA $11.64 Down -0.23 -1.94%
Momenta Pharmaceut… CAPS Rating: ***
NVS $80.73 Down -0.75 -0.92%
Novartis CAPS Rating: ****